Search results

This paper aims to focus on the utilisation of pre- and probiotics for oral care and the state of knowledge at this time.

Pre- and probiotics describe beneficial carbohydrates and microbiota, respectively, for optimal gut health. Carbohydrates provide energy selectively for the gut-friendly bacteria. The use of both carbohydrates and bacteria is, however, being expanded into other areas of the body – including the skin, vagina and oral cavity – for health-related applications.

There is increased interest in both pre- and probiotics for oral care products. The importance of oral microflora and their selective substrates is discussed against a background of contemporary oral care approaches. The issues and benefits are discussed in this review.

It is clear that consumption of prebiotics and probiotics may play a role as potential prophylactic or therapeutic agents for reducing the presence of organisms in the mouth associated with tooth decay. To confirm a beneficial effect of pre- and probiotics further in vivo studies involving healthy human volunteers should be considered.

The purpose of this paper is to determine the effect of synbiotic combination of lactobacilli with konjac glucomannan hydrolysate (GMH) to reduce Streptococcus mutans growth in vitro with the intention of characterising its efficacy as a new approach for oral hygiene.

Strains of Lactobacillus acidophilus and S. mutans were grown individually or in combination in modified Columbia base broth supplemented with 2 per cent GMH. Following incubation, the samples were plated on De Man, Rogosa and Sharpe and Columbia blood agar and growth of both strains was assessed.

The probiotic bacteria L. acidophilus was able to “out grow” S. mutans in the presence of konjac glucomannan in the mixed cultures.

The results indicate that consumption of prebiotic and probiotic combinations may play a role as potential prophylactic or therapeutic agents for reducing the presence of organisms in the mouth associated with tooth decay. In order to confirm a beneficial effect of GMH further in vivo in this concept, studies involving healthy human volunteers should be considered.

The aim of this study is to determine the effects of depolymerised mannans and specifically konjac glucomannan hydrolysates (GMH) on the colonic microflora of mice. Blood glucose and cholesterol were also measured.

Two groups (n = 20) of 12‐week old Wister mice were used for a period of 14 weeks. One group (treatment group) were fed diets containing 5 per cent konjac GMH dissolved in drinking water in addition to the control (group) standard diet. Faecal microflora, feed consumption, body weight, blood glucose and cholesterol were determined.

The GMH promoted the growth of anaerobes and lactobacilli in the treatment group where this was statistically, highly significant (P < 0.001). Also, the hydrolysate was able to reduce highly significantly (P < 0.001) faecal Clostridium perfringens and Escherichia coli counts. A significant increase in average daily feed consumption (P < 0.05) and weekly body weight (P < 0.001) was found for the treatment group. The mean ± SD (mmol/l) of blood glucose and cholesterol was lower in the treatment group.

In addition to modulating the gut microflora, GMH seems to lower the blood glucose and cholesterol in mice. Although this needs to be verified by further studies, GMH could also be a candidate for possible treatment of subjects with high cholesterol and for diabetics.

The purpose of this paper is to investigate how synbiotic combinations of lactobacilli with konjac glucomannan hydrolysate (GMH) may be used to reduce Staphylococcus aureus (S. aureus) and Salmonella typhimurium (S. typhimurium) growth in vitro.

Growth of S. aureus and S. typhimurium was assessed individually and when mixed with L. acidophilus in modified media supplemented with two per cent GMH. The effect of the GMH and the Lactobacillus strain on S. aureus growth was also investigated using the well diffusion test on Muller‐Hinton agar medium.

The results showed that L. acidophilus “out grew” the pathogens S. aureus and S. typhimurium in the presence of konjac glucomannan in the mixed cultures.

The paper demonstrates that konjac glucomannan hydrolysates combined with probiotic bacteria, may be used to inhibit the growth of pathogenic bacteria such as S. aureus and S. typhimurium. These data support the development of an alternative approach to reduce infections and promote consumer health.

This paper aims to evaluate the effect of depolymerised glucomannan in regulating blood lipid and glucose concentrations.

Twenty adult volunteers were recruited. Blood samples were taken at Day 0. The volunteers consumed drinks containing 3.0 g active glucomannan hydrolysates (AMH) for 14 days, after which time blood samples were retaken (Day 15). Blood samples were analysed to determine the blood lipid and glucose concentrations.

The average fasting blood glucose at the start of the trial was 2.54 mmol/L but reduced slightly to 2.49 mmol/L after consumption of the glucomannan. The total average cholesterol at the start of the trial was higher (6.69 mmol/L) than desirable ( < 5.0 mmol/L). This was reduced after consuming the glucomannan to 6.44 mmol/L (3.74 per cent). The triglyceride content was also higher initially than recommended (2.88 mmol/L) but was reduced by 11.5 per cent. The high-density lipoprotein (HDL) was within the desirable range before and after consumption (1.57 and 1.52 mmol/L, respectively), while the average low-density lipoprotein (LDL) was higher than recommended ( < 3.0 mmol/L), representing 4.55 mmol/L and 4.40 mmol/L before and after consumption, respectively. Both parameters were reduced by over 3.0 per cent. The consumption of the glucomannan hydrolysates also reduced the total cholesterol/HDL and LDL/HDL ratios.

The AMH was effective in lowering blood cholesterol and glucose concentrations. Consumption of such carbohydrates could prove useful for these physiological disorders. Further studies are desirable to characterise the exact mechanism.